Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it will host a conference call on Monday, March 14, 2016 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2015, and recent corporate highlights.
Conference Call and Webcast
| Date: | March 14, 2016 | |
Time: | 4:30 PM ET | |
Telephone Access: | Domestic Callers: dial (877) 458-0977 | |
| International Callers: dial (484) 653-6724 | ||
| Please reference the Akebia conference call | ||
| Passcode: 67706535 | ||
Online Access: | Go to the Investor Relations section of the Akebia website and follow instructions for accessing the live webcast. Please connect to the website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. An archived presentation will be available for 90 days. | |
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with chronic kidney disease (CKD) through hypoxia-inducible factor (HIF) biology. Akebia has commenced Phase 3 development of its lead product candidate, vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to CKD.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308006522/en/
Contacts:
Investors:
Susan Kim,
212-600-1902
Susan@argotpartners.com
or
Media:
Elizabeth
Schleifstein, 917-763-8106
Eliza@argotpartners.com
